First Beijing Investment Ltd has established a new position in Legend Biotech (LEGN), acquiring 2,296,335 shares valued at approximately $43.78 million during the first quarter of 2026. According to an SEC filing dated May 13, the position’s quarter-end value was reported at $41.54 million, reflecting price movements since the purchase. This stake represents 1.79% of First Beijing’s 13F reportable assets under management.
The addition of Legend Biotech comes as the company focuses on developing cell therapies for cancer, including a promising CAR-T product candidate. Despite the stock’s recent struggles—down 0.5% year-over-year and underperforming the S&P 500 by 25.7 percentage points—First Beijing’s entry signals a cautious foray into the biotechnology sector, diversifying its concentrated portfolio primarily composed of Chinese tech and consumer stocks.
For investors, this move highlights the potential for growth in the oncology space, particularly through strategic partnerships like the one with Janssen Biotech. However, the limited size of the position suggests a tentative approach rather than a strong conviction in Legend Biotech’s near-term prospects.
Source: fool.com